*Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the prospectus dated September 13, 2010 (the "**Prospectus**") issued by MicroPort Scientific Corporation (the "**Company**").*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement and the information contained in this announcement are not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"). The Shares may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. No public offering of the securities will be made in the United States.*

MicroPort

MicroPort Scientific Corporation

微 創 醫 療 科 學 有 限 公 司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 853)

FULL EXERCISE OF OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option referred to in the Prospectus has been fully exercised by Credit Suisse (Hong Kong) Limited (the "**Stabilizing Manager**") on behalf of the International Purchasers on September 24, 2010 in respect of an aggregate of 37,911,000 new Shares (the "**Over-allotment Shares**") to be allotted and issued by the Company, in aggregate representing approximately 15% of the Offer Shares initially available under the Global Offering (assuming no exercise of the Over-allotment Option), for the sole purpose of covering over-allocations in the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK$6.10 per Share (excluding brokerage of 1.0%, SFC transaction levy of 0.004% and Stock Exchange trading fee of 0.005%), being the Offer Price per Share in connection with the Global Offering.

The Company makes this announcement pursuant to section 9(2) of the Securities and Futures (Price Stabilising) Rules (Cap. 571W of the Laws of Hong Kong).

1. EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option referred to in the Prospectus has been fully exercised by the Stabilizing Manager on behalf of the International Purchasers on September 24, 2010 in respect of the Over-allotment Option Shares, in aggregate representing approximately 15% of the Offer Shares initially available under the Global Offering (assuming no exercise of the Over-allotment Option), for the sole purpose of covering over-allocations in the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK$6.10 per Share (excluding brokerage of 1.0%, SFC transaction levy of 0.004% and Stock Exchange trading fee of 0.005%), being the Offer Price per Share in connection with the Global Offering.

Listing of and permission to deal in the Over-allotment Shares have already been granted by the Listing Committee. Listing of and dealing in such Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9.30 a.m. on Monday, September 27, 2010.

The shareholding structure of the Company immediately before and immediately after the issue of the Over-allotment Shares by the Company are as follows:

	After the Global Offering but immediately before the issue of the Over-allotment Shares by the Company		**After the Global Offering but Immediately after the issue of the Over-allotment Shares by the Company**	
Shareholder	**Number of Shares**	**Approximate % of issued share capital**	**Number of Shares**	**Approximate % of issued share capital**
Otsuka Pharmaceutical[(1)]	468,994,120	33.4%	468,994,120	32.5%
Shanghai ZJ[(2)]	285,748,050	20.4%	285,748,050	19.8%
We'Tron Capital[(3)]	217,110,000	15.5%	217,110,000	15.1%
Connected person employee Shareholders[(4)]	25,139,240	1.8%	25,139,240	1.7%
Employee Shareholders other than connected persons[(4)]	47,052,580	3.4%	47,052,580	3.3%
Other public Shareholders[(5)]	360,068,350	25.6%	397,979,350	27.6%
Total	**1,404,112,340**	**100%**	**1,442,023,340**	**100%**

Note:

(1) Otsuka Pharmaceutical is a wholly owned subsidiary of Otsuka Holdings.

(2) The ultimate shareholder of Shanghai ZJ is the State-owned Assets Supervision and Administration Commission of the Shanghai Pudong New Area People's Government.

(3) Dr. Zhaohua Chang, the founder, Director and chairman of the Company, owns 49% equity interest in, and thus controls, Shanghai We'Tron which in turn owns 94.19% equity interest in We'Tron Capital.

(4) "Connected person employee Shareholders" and Employee Shareholders other than connected persons" include the Company's employees and former employees who became Shareholders as a result of the exercise of their share options under the Pre-IPO Share Option Schemes or the purchase of Shares from current or former Shareholders.

(5) "Other public Shareholders" include Gao Yang Investment Corporation, Essex Woodlands Health Ventures Fund VII, L.P., Qi Capital Corporation and World Accord Limited, all of which are independent of the Group and of each other.

The net proceeds received by the Company from the Global Offering before the exercise of the Over-allotment Option, after deduction of related underwriting commissions and expenses, are approximately HK$1,428.3 million. The additional net proceeds to be received by the Company upon the exercise of the Over-allotment Option are estimated to be approximately HK$194.1 million. The total net proceeds from the Global Offering to be received by the Company as a result of the exercise of the Over-allotment Option are approximately HK$1,622.4 million.

Please refer to the section "Future Plans and Use of Proceeds" in the Prospectus for information on the intended use of proceeds.

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules. No new Shares or securities convertible into equity securities of the Company may be issued within six months from the Listing Date save for the situations set out in Rule 10.08 of the Listing Rules.

2. REFERENCE TO THE ALLOTMENT RESULTS ANNOUNCEMENT DATED SEPTEMBER 22, 2010

Reference is made to the allotment results announcement dated September 22, 2010 in relation to the election forms which were sent to the 521 applicants whom the Receiving Bankers were unable to contact, who had applied using the mistakenly printed Yellow Forms prior to 4:00 p.m. on September 16, 2010 and who were allotted Shares. The Joint Bookrunners noted that as at 6:00 p.m. on September 24, 2010, 273 of the 521 applicants (the "**Remaining Applicants**") (approximately 390,000 Shares were allotted to these Remaining Applicants) had not reverted with their option pursuant to the election form. The Joint Bookrunners will be contacting these Remaining Applicants with a proposed offer ("**Offer Letter**") to compensate them for their losses arising out of the on-the-market sale (if any) of their allotted Shares (such Shares are not subsequent purchases from the market) at the Stock Exchange at a trading price below the Offer Price between September 24, 2010 to September 30, 2010 (inclusive), subject to the terms and conditions stated therein in the Offer Letter. The details of the compensation offer and the calculation of such losses will be stated clearly in the Offer Letter.

By order of the board of
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Hong Kong, September 26, 2010

As at the date of this announcement, the executive Directors are Dr. Zhaohua Chang, Ms. Yan Zhang, Mr. Hongbin Sun and Mr. Qiyi Luo; the non-executive Directors are Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji and Mr. Xiaolong Liu; and the independent non-executive Directors are Mr. Zezhao Hua, Mr. Jonathan H. Chou and Dr. Guoen Liu.

** for identification purpose only*